U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Substance Use Tools & Resources   

Read the Guide

This collection of tools and resources is for providers, staff, and patients who offer or use services to address substance use, and other interested stakeholders. This collection was originally established following an environmental scan on implementing medication-assisted treatment (MAT) for opioid use disorder (OUD) in rural primary care. (See PDFs of Volume 1 [PDF 0.69 MB] and Volume 2 [PDF 1.28 MB] of that scan). Items have been continuously added to this collection since then, and the collection has expanded to cover substance use more broadly, rather than just MAT for OUD.

Displaying 31 - 40 of 124

Substance Use Treatment Resource Guide for Black and Hispanic/Latinx Populations

This guide provides a detailed list of substance use-related resources for people who are at risk for a substance use disorder, their loved ones and the providers who work with them. Resources focus heavily on Black and Hispanic/Latinx populations, with acknowledgment of the wide diversity and overlap that exists among these populations.
Format
Toolkit
Audience
Patients
Families
Communities
Source
National Council for Mental Wellbeing
Year
Resource Type
PDF
File Size
1043 KB

Supporting People Experiencing Homelessness in Smoking Cessation

This Issue Brief looks at the impact of cigarette smoking, vaping, and other tobacco use among people experiencing homelessness, including children, teens, families, Indigenous communities with cultural experiences of medicinal tobacco use, and people who experience other forms of social marginalization.
Format
Report/Paper/Issue Brief
Audience
Behavioral Health Providers
Medical Providers
Communities
Source
National Health Care for the Homeless Council
Year
Resource Type
PDF
File Size
1580 KB

The Pharmacy Access to Resources and Medication for Opioid Use Disorder (PhARM-OUD) Guideline

This document seeks to help pharmacists balance the risks and benefits to themselves, their employer, and, most importantly, their patients that accompany each buprenorphine dispensing decision. The overarching recommendation of this document is that pharmacists should make a good faith effort to provide high quality care to persons with OUD by always maintaining an adequate supply of buprenorphine and filling legitimate prescriptions in a timely manner.
Format
Report/Paper/Issue Brief
Audience
Other Team Members
Source
National Association of Boards of Pharmacy and National Community Pharmacists Association
Year
Resource Type
PDF
File Size
606 KB

Treatment for Opioid Use Disorder: Population Estimates — United States, 2022

This article reviews medication for opioid use disorder (MOUD) treatments in the United States from data pulled from the 2022 National Survey on Drug Use and Health.
Format
Report/Paper/Issue Brief
Audience
Policymakers and Payers
States
Behavioral Health Providers
Communities
Source
Centers for Disease Control and Prevention (CDC)
Year
Resource Type
PDF
File Size
435 KB

VIP Community Services: An Opioid Treatment Program in the Bronx, New York

This case study explores implementation of a medications for opioid use disorder (MOUD) program at an organization in the Bronx, New York with a long history as an opioid treatment program (OTP) that also operates an FQHC and a certified community behavioral health clinic (CCBHC)
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Policymakers and Payers
Source
Centers for Health Care Strategies (CHCS)
Year
Resource Type
PDF
File Size
206 KB

Addiction Language Guide

This guide provides research about language, recommended language and rationale to avoid stigma around substance use, and implementation resources to address stigma in medical facilities.
Format
Guide
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
First Responders
Source
Shatterproof
Year
Resource Type
PDF
File Size
1.1 MB

Advisory: Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns

This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. It also focuses on the risks and harms of CBD and clarifies common misconceptions about CBD.
Format
Advisory
Audience
Patients
Families
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
PDF
File Size
1827 KB